Horizon scanning: Data for soluble ferric pyrophosphate for iron deficiency in haemodialysis patients

Source: BioSpace Area: News BioSpace has reported on the main results of a study evaluating soluble ferric pyrophosphate (SFP) for the treatment of iron deficiency in haemodialysis patients.   SFP is an iron compound that is delivered to the haemodialysis patient via dialysate replacing the 5-7mg of iron lost during a dialysis treatment. Once in the dialysate, SFP crosses the dialyser membrane and enters the bloodstream where it binds to apo-transferrin and is taken to the bone marrow.   The 9-month multicentre PRIME study randomised 108 patients (103 of whom received the study drug; modified intention-to-treat [ITT] population) to dialysate containing SFP-iron (n=52) or to conventional dialysate (n=51). Doses of erythropoietin stimulating agents (ESA) were titrated to maintain haemoglobin levels in a target range of 9.5 to 11.5 g/dL and intravenous iron was administered as needed to treat iron deficiency. The primary objective of the study was to determine whether regular administration ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news